Mounjaro Outperforms Ozempic in Weight Loss, Study Finds

FDA-approved higher doses of Mounjaro and Ozempic for weight loss, with Zepbound expected to become a popular choice due to its efficacy and minimal side effects.

Overweight and obese adults who took the diabetes medication Mounjaro, also known as tirzepatide, lost more weight and were more likely to meet specific weight loss targets than those on a similar competitor, Ozempic, according to a new study.
The study was initiated by Truveta, a data analytics company owned and operated by 30 US health care systems, and was not sponsored by either of the drugs’ manufacturers.
Both Mounjaro and Ozempic are prescribed to treat type 2 diabetes but have gained popularity because they may also help people lose substantial amounts of weight.
Because of their weight-loss benefits, the US Food and Drug Administration has approved higher doses of both tirzepatide and semaglutide for weight loss under the names Zepbound and Wegovy, respectively.
Experts anticipate Zepbound’s high efficacy and minimal short-term side effects could make it one of the most popular weight-loss drugs on the market.